Feels like the market’s punishing patience again. Predictable earnings, clear guidance, and suddenly it’s all doom. Kinda exhausting.
For long-term holders, does this selloff actually change growth trajectories, or is it just sentiment? How do you reassess multiples after these earnings?
From a trade angle, I’m watching BABA for a quick bounce into resistance, then selling rips. If it holds lows, I’ll add. Otherwise, I’ll fade any early rallies in JD and BIDU. Tight stops, no emotional entries.
Regulatory risk dominates over rate cuts in biotech.
For a small sleeve, is SRPT worth a starter position, or better to pair with MRNA for FDA-related beta?
Everyone hyped the 13 bounce, but SRPT keeps sliding. Feels like the market’s chasing noise again, not real FDA signals.
Semis are bruised, but I still like the secular trend. If NVDA can stabilize, IWM might re-rate. Not convinced yet.
Seen this movie before: panic spikes fade, then the next leg. But if rates stay sticky, rallies stay shallow. Not convinced this is a turning point.
Rates still elevated, growth softer, and the Fed cautious. Until CPI cools and jobs surprise, risk assets probably drift, not sprint.
This red feels like overreaction, not panic.
Market’s reacting to earnings miss and guidance, but volume’s light. Feels like nerves more than fundamentals.
NKE down 4.2% on 1.2M shares traded, EPS -$0.02 vs -$0.01, revenue $1.29B vs $1.32B. With 15% debt and 20% operating margin, I’d expect a bounce if guidance isn’t too weak.
Holding $TTWO, kinda excited but nervous about delays.
Everyone’s cheering paid time off, but I doubt it changes core engagement. Marketing cycles are long, and delays usually follow.
Big hype, but is this just another overpromised launch?
Seen this before—tech pullbacks, or just noise?
Hard to trade this; if it’s a real catalyst, why no follow-through volume? Feels like dead money chasing a headline.
Everyone cheering the dip, but volume looks thin.
